Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients

doi:10.4251/wjgo.v8.i2.222

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7620)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

562

WORD

467

HTML

3849

Figures (1-5)

234

Tables (1-3)

239

Sum=5351

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

997

Download

1272

Sum=2269

Feb 15, 2016 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Evidence-Based Medicine

World J Gastrointest Oncol. Feb 15, 2016; 8(2): 222-230
Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.222

Full Size Figure Download Figure

Figure 1 Overall survival in 41 metastatic colorectal cancer treated with cetuximab in II and III lines according to median basal level of invariant natural killer T cells (0. 382 cells/microliter). iNKT: Invariant natural killer T.

Citation: Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC. Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. World J Gastrointest Oncol 2016; 8(2): 222-230
URL: https://www.wjgnet.com/1948-5204/full/v8/i2/222.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i2.222